Vesiculopustular dermatosis: An uncommon side-effect of liraglutide?

被引：12
作者：
Besemer, Femke [1 ]
Verschoor, Arjan J. [1 ]
Diamant, Michaela [2 ]
Hoogma, Roel P. L. M. [1 ]
机构：
[1] Groene Hart Hosp, Dept Internal Med, NL-2800 BB Gouda, Netherlands
[2] Vrije Univ Amsterdam Med Ctr, Ctr Diabet, Amsterdam, Netherlands
来源：
JOURNAL OF DIABETES AND ITS COMPLICATIONS | 2012年 / 26卷 / 05期
关键词：
Liraglutide; Skin reaction; Pustules; Diabetes; TYPE-2; COMBINATION; METFORMIN; EFFICACY; PLACEBO; SAFETY; ANALOG;
D O I：
10.1016/j.jdiacomp.2012.05.018
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Liraglutide is a GLP-1 receptor agonist, a novel medication for type 2 diabetes. We describe a case of pustules in a patient recently started on liraglutide. Common side effects of liraglutide are gastrointestinal disorders. Skin and tissue reactions are less well-known side effects. Liraglutide could be the cause of skin eruptions in this patient, possibly by immunogenicity. (C) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码：458 / 459
页数：2
相关论文
共 9 条
[1]   Liraglutide Treatment Is Associated with a Low Frequency and Magnitude of Antibody Formation with No Apparent Impact on Glycemic Response or Increased Frequency of Adverse Events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) Trials [J].
Buse, John B. ;
Garber, Alan ;
Rosenstock, Julio ;
Schmidt, Wolfgang E. ;
Brett, Jason H. ;
Videbaek, Nicoline ;
Holst, Jens ;
Nauck, Michael .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (06) :1695-1702
[2]   Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) [J].
Buse, John B. ;
Rosenstock, Julio ;
Sesti, Giorgio ;
Schmidt, Wolfgang E. ;
Montanya, Eduard ;
Brett, Jason H. ;
Zychma, Marcin ;
Blonde, Lawrence .
LANCET, 2009, 374 (9683) :39-47
[3]   Enhancing incretin action for the treatment of type 2 diabetes [J].
Drucker, DJ .
DIABETES CARE, 2003, 26 (10) :2929-2940
[4]   Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial [J].
Garber, Alan ;
Henry, Robert ;
Ratner, Robert ;
Garcia-Hernandez, Pedro A. ;
Rodriguez-Pattzi, Hiromi ;
Olvera-Alvarez, Israel ;
Hale, Paula M. ;
Zdravkovic, Milan ;
Bode, Bruce .
LANCET, 2009, 373 (9662) :473-481
[5]   Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU) [J].
Marre, M. ;
Shaw, J. ;
Braendle, M. ;
Bebakar, W. M. W. ;
Kamaruddin, N. A. ;
Strand, J. ;
Zdravkovic, M. ;
Le Thi, T. D. ;
Colagiuri, S. .
DIABETIC MEDICINE, 2009, 26 (03) :268-278
[6]   Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes The LEAD (Liraglutide Effect and Action in Diabetes)-2 study [J].
Nauck, Michael ;
Frid, Anders ;
Hermansen, Kjeld ;
Shah, Nalini S. ;
Tankova, Tsvetalina ;
Mitha, Ismail H. ;
Zdravkovic, Milan ;
During, Maria ;
Matthews, David R. .
DIABETES CARE, 2009, 32 (01) :84-90
[7]   Review of the Therapeutic Uses of Liraglutide [J].
Ryan, Gina J. ;
Foster, Karla T. ;
Jobe, Lynetta Johnson .
CLINICAL THERAPEUTICS, 2011, 33 (07) :793-811
[8]   Glucagon-like peptide analogues for type 2 diabetes mellitus [J].
Shyangdan, Deepson S. ;
Royle, Pamela ;
Clar, Christine ;
Sharma, Pawana ;
Waugh, Norman ;
Snaith, Alisa .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2011, (10)
[9]   Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD) [J].
Zinman, Bernard ;
Gerich, John ;
Buse, John B. ;
Lewin, Andrew ;
Schwartz, Sherwyn ;
Raskin, Philip ;
Hale, Paula M. ;
Zdravkovic, Milan ;
Blonde, Lawrence .
DIABETES CARE, 2009, 32 (07) :1224-1230
1